All In Biotech

Drug Trial Radar · NCT02611973

Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia

French Aspirin Study in Essential Thrombocythemia: an Open and Randomized Study

Last checked: Nov 19, 2026Latest source record: Jul 26, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 2,250 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

2,250

Planned (sponsor's estimate)

Start

Mar 10, 2016

Primary completion

Nov 2019

Study completion Nov 2022

Sponsor

Lead sponsor
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 23, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The hypothesis is that efficient prevention of thrombosis with aspirin at diagnosis becomes less useful once patients have achieved a hematologic response (HR) (modified by amendment 1/03/2017) and/or that this benefit is hampered by an increased hemorrhagic risk especially in elderly patients. Hence, investigator propose a prospective randomized study to assess the benefit / risk ratio of aspirin maintenance in high risk Essential thrombocythemia (ET) patients, in hematological response (modified by amendment 1/03/2017) on Hydroxyurea.

Conditions

  • MPN
  • Essential Thrombocythemia

Interventions

  • Aspirin therapy interruptionOther

    Stop the treatment by aspirin 100mg/d in the experimental arm.

  • Usual treatment by aspirin 100 mg/d in the active comparator armOther

    HU+ aspirin maintenance

  • No interruption of aspirin in the Observational armOther

    patient with Contre indication to aspirin or required antithrombotic therapy

  • Hydroxyurea treatment (HU)Drug

    HU maintenance

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative incidence of death from vascular origin and other thrombotic and hemorrhagic events (combined endpoint)Time frame: at 2-years follow-up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Henri Mondor Hospital

    Créteil, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.